<!DOCTYPE html>
<html lang="en">
  <head>
    <title>Drop Down TableFill Activity</title>
    <meta http-equiv="content-type" content="text/html; charset=us-ascii" />
    <link
      href="https://learn.bcit.ca/shared/scripts/bootstrap-2.3.1/css/bootstrap.min.css"
      rel="stylesheet"
    />
    <script
      src="https://learn.bcit.ca/shared/scripts/jquery/jquery-1.8.3.min.js"
      type="text/javascript"
    ></script>
    <!-- LTC CP styles -->
    <link rel="stylesheet" href="https://ltc.bcit.ca/public/v1/css/bcit.css" />

    <link href="../scripts/ddm_v2.css" rel="stylesheet" />
  </head>
  <body>
    <table class="left">
      <thead>
        <tr>
          <th class="_ddm" width="20%">Drug</th>
          <th>Indications</th>
          <th class="_ddm" width="150px">Action</th>
          <th class="_ddm" width="20%">
            Key Points of Administration &amp; Mode of Administration
          </th>
          <th>Considerations</th>
          <th>Adverse effects/ Side effects</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td>Succinylcholine (Suxamethonium)</td>
          <td>
            Rapid sequence induction (especially in &nbsp;non-fasting patients),
            short-term procedures (i.e. intubation)
          </td>
          <td>Short-acting 2-5 mins, Pseudocholineste</td>
          <td>IV/IO IM dose should be double the IV dose</td>
          <td>
            Has a short duration and is associated with side effects, so it is
            not useful for long-term paralysis. Pseudocholinesterase deficiency
            can cause block &gt; 24 hrs
          </td>
          <td>
            Muscle pains Bradycardia (especially in infants), which may be
            prevented by atropine. Hyperkalaemia can lead to cardiac arrest -
            particularly with spinal injury, rhabdomyolysis and burns patients,
            raised intraocular, intracranial and intragastric pressure may
            trigger Malignant Hyperthermia in genetically susceptible patients
          </td>
        </tr>
        <tr>
          <td>Vecuronium</td>
          <td>ETT intubation, ongoing NMB for ventilated pts in PICU</td>
          <td>25 - 30 mins</td>
          <td>IV</td>
          <td>
            It has a slower onset than high-dose Rocuronium- but is
            shorter-acting than Pancuronium with minimal cardiovascular effects.
            It may be used in cardiovascular, pulmonary, and neurological
            emergencies in most patients.
          </td>
          <td>
            Caution in liver patientï¿½s elimination is via the liver.
            Accumulation with prolonged infusion can cause histamine release.
          </td>
        </tr>
        <tr>
          <td>Rocuronium</td>
          <td>
            At high doses, it produces good to excellent intubation conditions
            within 1 minute
          </td>
          <td>25-30 mins</td>
          <td>IV</td>
          <td>Metabolised by the liver and excreted by kidneys.</td>
          <td>
            Greater histamine release than vec, mild vagolytic, may increase HR
            by 10-20 beats per minute,
          </td>
        </tr>
        <tr>
          <td>Cisatracurium</td>
          <td>
            Low doses need to obtain paralysis, Good for liver and renal failure
            patients
          </td>
          <td>30-40 mins</td>
          <td>IV</td>
          <td>No histamine or haemodynamic side effects</td>
          <td>
            Allergic reactions can cause hives, tachycardia, hypotension, and
            bronchospasm (rare, in &lt;1% of patients). Anticonvulsants can
            decrease the effect of Cis.
          </td>
        </tr>
        <tr>
          <td>Pancuronium</td>
          <td>has a slower onset but lasts longer</td>
          <td>30-60 mins</td>
          <td>IV</td>
          <td></td>
          <td>
            It can produce vagolytic effects (e.g., increased HR and BP ) and,
            therefore, may be BENEFICIAL for preserving blood pressure and heart
            rate in certain patient groups- infants and cardiac patients.
            Excreted by the kidneys, therefore, it is contraindicated in renal
            failure.
          </td>
        </tr>
      </tbody>
    </table>

    <script src="../scripts/ddm_v2.js" type="text/javascript"></script>
  </body>
</html>
F
